Učitavanje...
Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review
Nitric oxide/cyclic guanosine monophosphate (cGMP) signaling is compromised in Alzheimer’s disease (AD), and phosphodiesterase 5 (PDE5), which degrades cGMP, is upregulated. Sildenafil inhibits PDE5 and increases cGMP levels. Integrating previous findings, we determine that most doses of sildenafil...
Spremljeno u:
| Izdano u: | J Alzheimers Dis Rep |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
IOS Press
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7242821/ https://ncbi.nlm.nih.gov/pubmed/32467879 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/ADR-200166 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|